Founded in 1977, the Macula Society is a forum for new research in retinal vascular and macular diseases. Membership is by application, with acceptance criteria including extensive contribution to retinal literature. The Macula Society recognizes outstanding achievement by its members and others through awards and lectures, and holds an annual meeting open to members, their guests co-authors, and supporting company representatives.
The 37th Annual Macula Society Meeting will be held this coming week from February 19th through February 22nd at the Ocean Reef Club in Key Largo, FL. Dr. Michael Elman, M.D, who has been running an ongoing Investigator Sponsored Trial that has been using Squalamine in proliferative diabetic retinopathy as as monotherapy, will be giving a presentation entitled “Regression of Retinal Neovascularization in Proliferative Diabetic Retinopathy using Squalamine Lactate Eye Drops” on Wednesday, February 19th.
Dr. Michael Elman, M.D., a board certified ophthalmologist, has practiced ophthalmology for over 30 years, specializing in diseases of the retina and vitreous. He is the author of more than 150 publications on retinal diseases and surgery. Dr. Elman is an Assistant Professor of Ophthalmology at the Johns Hopkins University School of Medicine. He is currently the Director of Retina Surgery at Franklin Square Hospital. Dr. Elman directed the Clinical Research Unit at the University of Maryland and was bestowed the Young Scholar Award for the entire University of Maryland. He serves as the Chairman of Executive Committee of the National Eye Institute’s Diabetic Retinopathy Clinical Research Network (DRCRnet). He was also Study Chairman of the DRCRnet’s Protocol I, a national collaborative clinical trial that recently revolutionized the treatment of diabetic macular edema.
Dr. Michael Elman, M.D. is currently also serving on the Scientific Advisory Board (“SAB”) for Ohr Pharmaceutical (NasdaqCM: OHRP) comprised of leading retinal ophthalmology experts to assist in advancing the Squalamine eye drop program into clinical efficacy trials. He is joined by Thomas A. Ciulla, M.D. of the Midwest Eye Institute, Michael J. Elman, M.D. of the Elman Retina Group, and Jason S. Slakter, M.D. of the Vitreous Retina Macula Consultants of NY.
Ohr Pharmaceutical is focused on the development of novel therapeutics for serious medical conditions. Ohr’s Squalamine Eye Drop clinical program is evaluating a non-invasive solution for the treatment of the wet form of age-related macular degeneration (wet AMD). Current treatment options for wet-AMD patients involve chronic injections directly into the eye.
To learn more about Ohr Pharmaceutical (NasdaqCM: OHRP) please visit the Vista Partners’ website at the following link where one can find a dedicated company page that includes the latest company and industry news, videos, links to SEC filings, a FREE Report & more.
The post A Vista Partners’ Commentary “Ohr Pharmaceutical (OHRP) SAB Member Dr. Michael Elman, M.D. Presenting at 37th Annual Macula Society Meeting On Wednesday, February 19th” appeared first on Vista Partners.